Zofran Lawsuit Seeks Damages From GlaxoSmithKline

November 16, 2015 – – ZofranLegal.com reports on another lawsuit filed against GlaxoSmithKline and their anti-nausea drug Zofran. Similar to the more than 60 other Zofran lawsuits, this one states that a child’s exposure to the drug while developing in utero caused them to be born with “numerous congenital defects.” The mother in this particular case resides in Arkansas. Her claim was filed in the United States District Court for the Eastern District of Louisiana under number 2:15-cv-04399-SM-DEK.

The suit was filed on September 14th of 2015, and seeks damages from pharmaceutical conglomerate GlaxoSmithKline. It claims, as so many others do, that GSK has purposefully hidden mounting evidence linking Zofran to birth defects in infants. The woman’s complaint details another tragic story which current Zofran lawsuit plaintiffs are all too familiar with.

The mother states that she was experiencing severe nausea due to morning sickness, and was prescribed Zofran to treat it. She used the drug during the first trimester, a time that women commonly experience morning sickness, and also a time when the fetus does much of its heart, limb, and mouth development. When the woman later gave birth to a son in 2007, the infant boy was immediately diagnosed with birth defects that physicians termed “severe.”

According to details found within the complaint, these defects included a cleft palate, bilateral clubfeet, respiratory distress syndrome, and apnea.

Statistically speaking, cleft palate defects were noted in at least 11 other zofran birth defect lawsuits, and were linked to fetus zofran exposure by researchers from Boston University in 2012. The child, who is now age 8, has already undergone two surgeries to address these conditions.

Interestingly enough, zofran was never approved to treat expectant mothers, nor tested for safety in this aspect. The drug was approved by the U.S. Food and Drug administration in 1991 specifically to treat individuals suffering from nausea and vomiting after chemotherapy, radiation, or anesthesia. In the lawsuits filed against GSK,plaintiffs allege that despite this fact, the zofran manufacturer promoted the drug for use during pregnancy, both to the general public and to Ob/Gyns across the nation. This “off-label” marketing, many say, is what has caused the drug to be prescribed to countless expectant mothers.

The lawsuits currently filed against zofran have been consolidated to form multidistrict litigation in Boston, Massachusetts. As they await trial, it is expected that additional suits will continue to be filed. The attorneys at Monheit Law are currently working to assist anyone who used zofran while pregnant and who later gave birth to a child with defects. These individuals and their children may be entitled to compensation, and deserve to be able to explore their legal rights. At this time, Monheit Law is offering free consultations to anyone involved.

To obtain additional information on zofran birth defects, or to ask questions, please call Michael Monheit, Esq. at 877-620-8411.

###

Contact ZofranLegal.com:

Michael Monheit
1-877-620-8411
michael@monheit.com
1368 Barrowdale Road, Rydal, PA 19046

ReleaseID: 60005472